CG Oncology (NASDAQ:CGON) Shares Down 8.7% – Should You Sell?

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report)’s share price was down 8.7% during mid-day trading on Tuesday. The company traded as low as $75.44 and last traded at $77.3750. Approximately 376,593 shares traded hands during trading, a decline of 67% from the average session volume of 1,139,290 shares. The stock had previously closed at $84.78.

CG Oncology News Summary

These are some of the CGON news items that stood out recently:

  • Positive Sentiment: CG Oncology reported that its Phase 3 PIVOT-006 trial met its primary endpoint: cretostimogene reduced the risk of bladder-cancer recurrence by 68% versus surveillance (hazard ratio 0.32; p<0.0001). The company also reported no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results could support a future treatment option in a patient group with no FDA-approved adjuvant therapies. PIVOT-006 Phase 3 results
  • Neutral Sentiment: The company plans to submit a BLA for intermediate-risk and high-grade Ta disease in Q2 2027 and expects to complete an expanded BLA submission for BCG-unresponsive disease by the end of March 2027. These timelines offer potential catalysts, but regulatory review and approval remain ahead. Company trial and filing update
  • Negative Sentiment: The Phase 3 announcement is based on topline data, which may change after full analysis. The FDA could require additional evidence, delay review, or approve a narrower label than the company expects; cretostimogene’s safety and efficacy have not yet been established by the FDA.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CGON. Piper Sandler boosted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Friday, August 7th. JPMorgan Chase & Co. set a $113.00 price target on CG Oncology in a research report on Tuesday. Royal Bank Of Canada downgraded CG Oncology from an “outperform” rating to a “sector perform” rating and boosted their price target for the company from $80.00 to $97.00 in a research note on Tuesday. HC Wainwright increased their price objective on CG Oncology from $100.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Truist Financial restated a “buy” rating and issued a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CG Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.11.

Read Our Latest Research Report on CGON

CG Oncology Stock Down 6.5%

The stock has a market cap of $7.08 billion, a price-to-earnings ratio of -28.70 and a beta of 0.35. The stock’s 50 day moving average price is $68.24 and its two-hundred day moving average price is $66.70.

CG Oncology (NASDAQ:CGON – Get Free Report) last posted its earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. On average, analysts predict that CG Oncology, Inc. will post -3.00 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the transaction, the director owned 1,000 shares of the company’s stock, valued at $62,060. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of CG Oncology in the second quarter valued at approximately $444,509,000. Bank of America Corp DE purchased a new position in shares of CG Oncology during the 2nd quarter valued at approximately $69,978,000. Jefferies Financial Group Inc. acquired a new stake in CG Oncology in the 2nd quarter valued at $54,705,000. Toronto Dominion Bank grew its stake in CG Oncology by 177.7% in the 3rd quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock valued at $56,618,000 after acquiring an additional 511,044 shares during the period. Finally, Seven Fleet Capital Management LP grew its stake in CG Oncology by 24.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock valued at $134,017,000 after acquiring an additional 371,085 shares during the period. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

See Also

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.